🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

UFP Technologies, Inc. UFPT R2KR3KPHARMA

Healthcare · Medical Devices · United States
https://www.ufpt.com
Company Profile ↓
$295.78
+30.52% 1Y
Mkt Cap$2.29B
P/E31.98
P/B4.63
52W High$334.84
52W Low$185.28
Book Value$59.70
EPS (TTM)$9.25

Company Overview

UFP Technologies, Inc., together with its subsidiaries, designs and manufactures solutions for medical devices, sterile packaging, and other engineered custom products in the United States. The company provides protective drapes for robotic surgery, patient handling and comfort, advanced wound care, infection prevention, disposables for surgical and endoscopic procedures, packaging for medical devices, orthopedic implants, components for cardiac implants, dispenser coils for catheters, and biopharma drug manufacturing. It also offers equipment protection and packaging for firearms, unmanned aerial vehicles/drones, weapon systems, electronic devices communications equipment, and tools and repair kits; cushion and protective packaging; acoustic and thermal insulation components for automotive, aerospace, consumer, and industrial; filtration for small engines, air conditioners, humidifiers, refrigerators, electronic air cleaners, forced air appliances and industrial compressors; fluid management; and seals and gaskets for automotive manufacturing chemical processing, building and construction applications. In addition, the company provides uniform and tactical gear, such as backpack straps and padding, uniform knee and elbow pads, duty belts, holsters, and helmet padding and others; sports and leisure including custom helmet linings, athletic braces, and shoe insoles; and trim and structural components, consist of load floors, sunshades, package trays, back panel, and seat backs. The company serves the medical, aerospace and defence, automotive, consumer, electronics, and industrial markets. It markets and sells its products through a direct sales force. The company was founded in 1963 and is headquartered in Newburyport, Massachusetts.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.1%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 15.9%.

Consistent Profit Growth

Net profit has compounded at 16.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.9% CAGR over the past five years.

Healthy Margins

Operating margin of 16.2% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.29.

Recent Developments

  • Dec 2025 Revenue of $602.80M (+19.5% YoY); net profit $68.31M.
  • Trailing 12 Months Year-on-year growth — revenue +15.1%, earnings +21.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.9%, profit CAGR 16.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.94%
1 Year:15.10%

Compounded Profit Growth

5 Years:16.50%
1 Year:21.30%

Stock Price Performance

1 Year:+30.52%
6 Months:+47.85%
3 Months:+18.96%
1 Month:-0.90%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 74% of range
$185.28 $334.84
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)52.79 · Neutral
Price Performance
1M-0.90%
3M+18.96%
6M+47.85%
1Y+30.52%
Valuation vs Sector

P/E of 31.98 is above the sector median of 25.45 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 11.9% over 5 years.
  • Profit CAGR of 16.5% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
31.98
Industry PE
25.45
Forward P/E
24.91
PEG Ratio
3.80
Book Value
$59.70
Price to Book
4.63
P/S
3.39
EV/EBITDA
19.59
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
11.94%
Profit 5Y
16.50%
Revenue (YoY)
15.10%
Earnings (YoY)
21.30%

Profitability & Returns

ROCE
15.91%
ROE
17.05%
ROA
9.13%
Profit Margin
11.45%
Op Margin
16.19%
Gross Margin
28.50%
EPS (Latest Qtr)
$2.68
EPS (TTM)
$9.25

Balance Sheet & Liquidity

Debt/Equity
0.29
Quick Ratio
1.61
Current Ratio
3.00
Debt
$136.34M
Total Assets
$681.91M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
3.81%
Chg in Prom Hold
-0.18%
FII / Inst Holding
125.88%
Chg in FII Hold
-1.45%

Financial Snapshot

Enterprise Value
$2.29B
Total Revenue (TTM)
$631.64M
EBITDA
$115.91M
Free Cash Flow
$34.87M
Operating Cash Flow
$71.58M
Shares Outstanding
7.75M
Gross Margin
28.50%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 UFPT UFP Technologies, Inc. R2KR3KPHARMA 295.78 31.98 $2.29B 0.00% 15.91% 17.05% 11.94% 16.50%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue --------------------------97.75M100.04M100.78M101.50M105.01M110.18M145.16M144.07M148.15M151.18M154.56M148.91M154.20M173.96M
Gross Profit 8.45M8.18M9.52M9.94M8.19M7.84M10.19M12.99M12.43M12.71M12.50M14.37M13.32M13.77M12.82M9.95M10.53M11.38M12.61M13.41M12.02M13.07M17.13M24.32M25.52M23.28M28.70M29.64M27.75M26.13M30.08M33.03M41.52M42.06M42.15M43.54M42.75M41.97M44.36M50.92M
Operating Income 4.08M-3.21M3.93M2.50M-2.56M5.67M5.88M-5.25M6.57M6.14M-5.08M2.99M3.73M-5.30M6.21M5.08M-6.36M12.20M25.96M-12.84M17.04M15.04M-15.92M17.95M24.76M-23.13M24.33M23.38M-23.37M28.10M
Net Income 2.67M-2.17M2.63M1.70M-1.78M3.99M4.13M-3.73M4.60M5.64M-3.89M2.32M2.99M-4.16M4.71M3.79M-4.86M8.93M19.54M-9.74M11.88M11.69M11.61M12.69M13.55M16.36M16.38M17.18M17.18M16.38M17.57M17.50M20.85M
Diluted EPS 0.370.200.300.360.230.370.240.540.560.590.000.620.750.770.520.310.400.550.550.620.500.420.641.172.561.101.271.551.521.511.641.752.112.102.212.212.112.252.242.68

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 99.23M120.77M127.24M130.96M139.22M139.31M138.85M146.13M147.84M190.46M198.38M179.37M206.32M353.79M400.07M504.42M602.80M
Gross Profit 26.72M34.62M36.24M38.32M41.01M36.88M37.45M34.65M35.49M48.31M53.96M44.68M51.11M90.26M112.22M146.69M170.41M
Operating Income 8.19M14.39M15.72M16.67M17.40M11.56M11.71M12.24M11.69M19.61M24.71M16.73M21.22M55.40M57.66M80.90M92.34M
Net Income 5.93M9.25M10.35M10.89M11.28M7.56M7.59M7.97M9.21M14.31M19.75M13.37M15.89M41.79M44.92M58.98M68.31M
Diluted EPS 0.941.371.481.551.591.051.051.101.261.932.631.772.095.455.837.588.75
R&D Expense -900.00K1.20M1.30M1.20M1.40M1.30M1.30M5.00M10.50M8.80M8.20M8.50M9.30M7.20M10.40M8.60M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --69.48M79.72M98.62M104.91M112.55M119.64M127.93M138.21M189.60M188.76M203.20M334.13M378.19M404.14M629.00M655.08M
Total Equity 31.89M39.01M49.70M61.31M73.26M85.59M94.99M103.57M113.05M123.71M140.46M161.99M176.89M194.45M237.54M286.09M342.76M423.88M
Cash & Equivalents 5.14M13.40M22.10M29.85M33.48M37.30M34.05M29.80M31.36M37.98M3.24M3.74M24.23M11.12M4.45M5.26M13.45M20.30M
Long Term Debt --6.85M5.64M8.31M2.87M1.87M859.00K856.00K-22.29M-071.00M51.00M28.00M176.88M122.95M
Total Liabilities --19.25M17.74M25.36M19.32M17.56M16.06M14.88M14.49M49.14M26.77M26.31M139.69M140.65M118.05M286.24M231.20M
Current Liabilities --10.17M9.47M13.23M12.32M11.61M10.67M9.56M9.94M20.66M16.78M15.14M38.78M55.96M58.21M76.30M74.86M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ------12.52M9.31M17.47M21.32M31.23M25.04M14.29M17.74M41.33M66.59M91.91M
Investing Cash Flow -------15.69M-7.19M-10.38M-82.33M-5.77M-4.26M-101.46M1.29M-10.49M-210.16M-27.60M
Financing Cash Flow -------1.08M-559.00K-475.00K26.27M-24.95M-285.00K74.05M-25.89M-30.02M152.39M-58.16M
Capital Expenditure -1.86M-3.29M-3.74M-11.99M-5.83M-13.44M-15.74M-7.21M-10.38M-5.43M-5.78M-4.37M-5.39M-13.78M-10.49M-9.66M-
Free Cash Flow -------3.22M2.10M7.09M15.89M25.45M20.67M8.90M3.96M30.84M56.94M-
Share Buybacks ------587.00K----------

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 26.9%28.7%28.5%29.3%29.5%26.5%27.0%23.7%24.0%25.4%27.2%24.9%24.8%25.5%28.1%29.1%28.3%
Operating Margin % 8.3%11.9%12.4%12.7%12.5%8.3%8.4%8.4%7.9%10.3%12.5%9.3%10.3%15.7%14.4%16.0%15.3%
Net Margin % 6.0%7.7%8.1%8.3%8.1%5.4%5.5%5.5%6.2%7.5%10.0%7.5%7.7%11.8%11.2%11.7%11.3%
ROE % 15.2%18.6%16.9%14.9%13.2%8.0%7.3%7.0%7.4%10.2%12.2%7.6%8.2%17.6%15.7%17.2%16.1%
ROCE % -24.3%22.4%19.5%18.8%11.5%10.8%10.3%9.1%11.6%14.4%8.9%7.2%17.2%16.7%14.6%15.9%

Shareholding Pattern

Insiders
3.81%
Institutions
125.88%
Public Float
130.87%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 14.74% 1.14M $329.83M
2 Wasatch Advisors LP 8.82% 683.26K $197.44M
3 Congress Asset Management Co 7.47% 578.77K $167.25M
4 Neuberger Berman Group, LLC 6.93% 537.04K $155.19M
5 Price (T.Rowe) Associates Inc 4.61% 357.33K $103.26M
6 Boston Trust Walden Corporation 4.34% 336.28K $97.17M
7 Vanguard Capital Management LLC 4.26% 329.62K $95.25M
8 State Street Corporation 4.04% 312.81K $90.39M
9 American Century Companies Inc 3.61% 279.98K $80.90M
10 UBS Group AG 3.29% 254.74K $73.61M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for UFPT

No recent headlines available.

UFPT — Frequently Asked Questions

What is the current share price of UFP Technologies, Inc. (UFPT)?

As of 2026-10-23 16:27 PDT, UFP Technologies, Inc. (UFPT) trades at $295.78 on NasdaqCM. Its 52-week range is $185.28 to $334.84.

What is the market capitalisation of UFPT?

UFP Technologies, Inc. (UFPT) has a market capitalisation of $2.29B on NasdaqCM.

What is the P/E ratio of UFPT?

UFPT trades at a trailing price-to-earnings (P/E) ratio of 31.98. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 4.63.

What is the return on equity (ROE) of UFPT?

UFPT has a return on equity (ROE) of 17.05%. Its return on capital employed (ROCE) is 15.91%.

Is UFPT a good stock to buy?

This page provides a data-driven analysis of UFP Technologies, Inc. (UFPT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space